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Yand 24 hours after the procedure. ST resolution was estimated at 90 minutes in the
worst lead.
RESULTS 82 patients (70 males, 12 females) with a mean age of 56,9  12,7 years were
evaluated. The results showed signiﬁcant reduction in both Qtc (mean 460.81  26.17
ms vs 439.19  18.43 ms ; p < 0,001) and Qtd (mean 60.68  7.57 ms vs 35.78  10.25
ms; p < 0,001) before and 24 hours after primary PCI while no signiﬁcant difference
was noticed in the Qtc (460.81  26.17 vs 454.39  35.89 ; p ¼ 0.19) and Qtd (60.68 
7.57 vs 59.17  7.54; p ¼ 0.20) before and 90 minutes after the procedure.
Preprocedural QTd values were similar in patients with and without ST resolution
(67  5.77 vs 62  7.53; p ¼ 0.10). 24h after PPCI QTd decreased only in patients with
ST resolution (34.61  9.04 vs 58.5  4.12; p <0.001). Multivariate analysis showed
that ST resolution was an independent predictor of QTd after successful recanaliza-
tion (standardized regression coefﬁcient ¼ -0.684; p ¼ 0.004).
CONCLUSIONS In addition to a successful opening of the culprit artery, myocardial
reperfusion must be achieved to improve electrical stability and reduce repolarization
heterogeneity. Recovery of myocardial electrical homogeneity is not immediate and
begins 24 hours after revascularization as assessed by QTc and QTd.
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BACKGROUND Bifurcation (BF) lesions remain a challenging lesion and often asso-
ciated with lower success rates. The aim of this study is to evaluate the impact BF
intervention in acute myocardial infarction (AMI) on the angiographic and clinical
outcomes of Asian population.
METHODS A total of 903 patients (pts) were underwent percutaneous coronary
intervention (PCI) for AMI between January 2004 and April 2009. Patients were
divided into two groups according to presence of a BF lesion in the infarct-related
artery: BF group (n¼ 332) and non BF group (n¼571). BF lesions were deﬁned if a side
branch (SB) diameter was 2.0 mm.
RESULTS BF group had more male gender, higher incidence of non ST elevation
MI(NSTEMI, 51.5% vs. 60.4%, p¼0.01), higher incidences of culprit lesion in left
anterior descending artery, left circumﬂex artery, and left main as compared with non
BF group. However, the level of peak values of cardiac enzyme and left ventricular
ejection (LVEF) were similar between the two groups. The six months angiographic
outcomes and the cumulative clinical outcomes up to two years including total death,
cardiac death, MI, and major adverse cardiac events (MACE) were similar between the
two groups. However, BF group had higher incidence of target lesion revasculariza-
tion (TLR), target vessel revascularization (TVR) and TVR-MACEs as compared with
non BF group (Table).
CONCLUSION Despite BF intervention in AMI is challenging, the six months angio-
graphic outcomes and 2 years clinical outcomes were similar between the two groups.
However, BF intervention in AMI had higher incidence of repeat revascularization.
Cumulative clinical outcomes up to 24 monthsVariable, n (%) Bifurcation (N[332) Non BF (N[571) P valueTotal Death (TD) 24 (9.6) 49 (11.0) 0.608Cardiac death (CD) 22 (8.8) 35 (7.9) 0.774Recurrent MI 13 (5.2) 13 (2.9) 0.146STEMI 9 (3.6) 9 (2.0) 0.221Revascularization 57(22.8) 63 (14.2) 0.005TLR (target lesion revascularization) 36 (14.4) 29 (6.5) 0.001TVR(target vessel revascularization) 41 (16.4) 40 (9.0) 0.004TLR MACE (CDþSTEMIþTLR) 57 (22.8) 63 (14.2) 0.005
All MACE (TD þMI þTLRþTVR) 66 (26.4) 97 (21.8) 0.192CRT-117
Combination Of Thrombus Aspiration, High-dose Statin, Adenosine And Platelet
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segment Elevation Acute Myocardial Infarction
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BACKGROUND Primary percutaneous coronary intervention (pPCI) is currently the
most effective treatment strategy in ST-segment elevation acute myocardial infarc-
tion (STEMI). A considerable number of patients, however, develop no-reﬂowphenomenon during pPCI. Compared to similar patients with adequate reﬂow, those
with the no-reﬂow phenomenon have a higher incidence of death, myocardial
infarction and heart failure. We have established a risk prediction model of no-reﬂow
in our previous studies, through which we were able to ﬁnd out patients at high risk
of no-reﬂow.
METHOD A total of 1217 patientswere admitted to our hospital during the enrolment for
AMI; Patients with high risk of no-reﬂow (no-ﬂow score  10, by using a no-ﬂow risk
prediction model) were randomly divided into control group and combination therapy
group. Patients in control group received conventional treatment, while patients in
combination therapy group received high-dose (80mg) atorvastatin pre-treatment,
intracoronary administration of adenosine (140mg/min/kg) during PCI procedure,
platelet membrane glycoprotein IIb/IIIa receptor antagonist (tiroﬁban, 10mg/kg bolus
followed by 0.15mg/kg/min) and thrombus aspiration. Myocardial contrast echocardi-
ography (MCE) was performed to assess the myocardial perfusion 72 hours after PCI.
Major adverse cardiac events (MACE) were followed up for six months.
RESULTS A total of 621 patients were enrolled, among which 216(34.8%) high risk
patients of no-reﬂow were selected by no-reﬂow risk prediction model. Patient de-
mographics, angiography and procedural data examined in different group had no
signiﬁcantly different. No-reﬂow occurred in 11 cases (11/405, 2.7%) in low risk pa-
tients, 38 cases (38/108, 35.2%) in control group and 3 cases (2.8%) in combination
therapy group. MCE at 72 hours after PCI procedure suggested a higher A  b value in
combination therapy group than that of control group (Figure 3, 4). Six months
clinical follow-up was obtained in 552 patients. Events rates are presented in Table 3.
There were 6(6.3%) events (1 death, 2 non-fatal MIs and 3 revascularizations) in
combination therapy group, signiﬁcantly lower than 12(13.2%) events (4 deaths, 3
non-fatal MIs and 5 revascularizations) in control group.
CONCLUSION Our study discovered that using no-ﬂow risk prediction model to
screen AMI patients who had been suffered with high risk of no-reﬂow, and pre-
treated them with combination treatment could signiﬁcantly lower the incidence of
no-reﬂow, and further improved the prognosis.CRT-118
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BACKGROUND Revascularization of culprit vessel is the goal of primary percutaneous
coronary intervention (PCI) in patients with acute ST elevation myocardial infarction
(STEMI) and multivessel disease (MVD) without hemodynamic compromise.
Although concurrent revascularization of signiﬁcant non-culprit lesions during
index procedure may reduce infarct size and health care costs; however its safety and
feasibility is still debatable. We compare short and long term outcome of
Staged versus Multivessel primary PCI in hemodynamically stable STEMI patients
with MVD.
METHODS A single-center, open label, randomized prospective study including
50 patients with acute STEMI and one or more signiﬁcant non-culprit lesions of
either type A or B (high peri-procedural revascularization success rate). Patients
were randomized to either culprit lesion PCI during index procedure followed by
PCI to other signiﬁcant lesions in a later session within 60 days (Staged revascu-
larization group, SR) or multi-vessel revascularization during index procedure
(MVR). Primary outcomes were composite of death, MI requiring hospitalization
(excluding periprocedural MI), target or non-target vessel revascularization (PCI or
coronary artery bypass grafting), and decreased renal function 3-5 days following
administration of radiographic contrast dye. Patients were followed over a period
of 12 months.
RESULTS Both groups were balanced as regards baseline clinical and angiographic
criteria. No signiﬁcant difference between both groups in number of lesions treated
(p¼0.718) or number of stents used (p¼0.908). Fluoroscopy time was longer in
MVR (p<0.001). Similarly, amount of contrast used was higher in MVR group
(p¼0.011). Similar rates of major adverse cardiac events at one year were observed
in both groups (22.8% and 25% in MVR and SR group respectively, p¼0.428).
Target vessel revascularization was also similar (9.1% in MVR and 8.3% in SR
group, p¼0.927). In spite of increased amount of contrast used in MVR group, there
was no signiﬁcant decrease in kidney function after 3-5 days compared to SR group
(p¼0.729).
CONCLUSION We may conclude from this pilot study that multivessel intervention
during primary PCI is feasible and safe compared to a staged PCI approach when non-
culprit lesions have high rate of peri-procedural success. To our knowledge, this is the
ﬁrst pilot trial in literature that suggest using lesion criteria and rate of peri-
procedural success to decide about the appropriate approach during primary PCI for
patients with acute STEMI and MVD.
